Dystonia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dystonia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2014', provides an overview of the Dystonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dystonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dystonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dystonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dystonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dystonia Overview 6
Therapeutics Development 7
Pipeline Products for Dystonia - Overview 7
Pipeline Products for Dystonia - Comparative Analysis 8
Dystonia - Therapeutics under Development by Companies 9
Dystonia - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Dystonia - Products under Development by Companies 12
Dystonia - Companies Involved in Therapeutics Development 13
Ipsen S.A. 13
Addex Therapeutics Ltd 14
EpiVax, Inc. 15
QRxPharma Limited 16
Advicenne Pharma 17
Dystonia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
abobotulinumtoxin A - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
T-9001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
onabotulinumtoxin A - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ADV-6979 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dipraglurant ER - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Dystonia - Recent Pipeline Updates 32
Dystonia - Dormant Projects 33
Dystonia - Product Development Milestones 34
Featured News & Press Releases 34
Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 34
Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators 35
Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1 35
Jan 29, 2013: Addex Therapeutics's Dipraglurant Reduces Motor Abnormalities In Preclinical Model Of Dystonia 36
Oct 01, 2012: Allergan Comments on Order Regarding Permanent Injunction against Merz Pharmaceuticals and Merz Aesthetics 37
Apr 12, 2011: Merz's XEOMIN Data To Be Presented At 63rd Annual Meeting Of American Academy Of Neurology 37
Sep 20, 2010: Merz Pharma Launches XEOMIN Patient Assistance Plan In Canada 38
Sep 07, 2010: MERZ Pharma's XEOMIN Listed With Regular Benefit Status On AHWDBL 38
Aug 02, 2010: FDA Approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm 39
Oct 29, 2009: Ipsen announces the launch of Dysport (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products under Development for Dystonia, H2 2014 7
Number of Products under Development for Dystonia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Dystonia - Pipeline by Ipsen S.A., H2 2014 13
Dystonia - Pipeline by Addex Therapeutics Ltd, H2 2014 14
Dystonia - Pipeline by EpiVax, Inc., H2 2014 15
Dystonia - Pipeline by QRxPharma Limited, H2 2014 16
Dystonia - Pipeline by Advicenne Pharma, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Dystonia Therapeutics - Recent Pipeline Updates, H2 2014 32
Dystonia - Dormant Projects, H2 2014 33